The tryptamine psilocybin exerts its hallucinogenic effects primarily through agonism of 5-HT2A receptors. 5-HT2A receptor expression fluctuates across the estrous cycle, driven by variation in estradiol level. Therefore, it is likely that the hallucinogenic effects of the drug may also vary across the estrous cycle. The head twitch response, also called wet dog shake, can […]
C48: Estrogen Improves Psilocybin Efficacy
Recent study of the hallucinogenic drug psilocybin points towards potential therapeutic benefits for serotonin-linked mood disorders, such as major depressive disorder and PMDD, a depressive disorder that is associated with women’s estrous cycles and the cycling of estradiol. The primary mechanism of action of psilocybin is agonistic on the 5HT2A receptor. Estradiol has been shown […]